The oncotropic phenotypes of several viruses correlate with tumor-associated deficiencies within interferon (IFN) signaling pathways. This observation formed the conceptual basis for developing oncolytic viruses deleted for viral proteins that inhibit the host IFN-dependent antiviral response, such as herpes simplex virus type-1 infected cell protein-0 (ICP0) and vesicular stomatitis virus matrix protein. Many viruses have evolved means to disrupt promyelocytic leukemia protein (PML) nuclear bodies. For example, ICP0 promotes PML degradation to inhibit the antiviral activities of this IFN-stimulated gene. As PML is downregulated in a variety of tumors, we hypothesized ICP0-null herpes simplex type-1 viruses are selectively oncolytic in tumors with impaired PML expression. We illustrate that ICP0-null herpes simplex type-1 viruses target tumor cells that either possess impaired PML signaling or cannot upregulate PML because of impaired IFN responsiveness. Disruption of PML signaling through overexpression of the dominant-negative protein PML-retinoic acid receptor alpha in PML-positive cells renders them sensitive to oncolysis by ICP0-null herpes simplex virus type-1 and vesicular stomatitis virus M protein mutant viruses, whereas PML overexpression reverses this phenomenon. Together, these data illustrate that PML mediates an antiviral mechanism that predicts the tropism of IFN-sensitive oncolytic viruses. To our knowledge, these viruses are the first examples of anti-cancer therapeutics capable of targeting deficiencies in PML expression.
Introduction
Replication-competent oncolytic viruses (OVs) have recently gained prevalence as valuable tools in cancer therapeutics. Numerous preclinical and clinical studies on OVs have underscored their ability to safely disseminate and kill cancerous cells, leaving the surrounding normal cell populations intact. 1 Despite these advances, there is a lack of understanding of the molecular underpinnings that promote or inhibit the success of OV-mediated tumor cell lysis. 2 Various tumor types possess defective components of interferon (IFN) signaling pathways, [3] [4] [5] [6] allowing the tumor to subvert IFN's anti-proliferative and proapoptotic functions. 7, 8 Once secreted, type I IFNs (IFNa/b) upregulate IFN-stimulated genes, 9 which in turn mediate antiviral and anti-proliferative effects by promoting apoptosis, modulating cell cycle progression, inhibiting angiogenesis and regulating immune cell recognition. 10 Considering IFN's antiviral properties, it is not surprising that viruses have evolved countermeasures to circumvent IFN-mediated antiviral programs. For example, vesicular stomatitis virus (VSV) matrix (M) protein prevents host messenger RNA transcript export from the nucleus to the cytoplasm, 11 whereas the herpes simplex virus (HSV) infected cell protein-0 (ICP0) blocks upstream IFN-b gene expression. 12, 13 Accordingly, the oncolytic activities of VSV M protein mutants and ICP0-null HSVs correlate with tumor-associated defects in IFN signaling. 14, 15 Moreover, a variety of tumor suppressors have been shown to be regulated by IFN, 16, 17 including ribonuclease L 6 and promyelocytic leukemia protein (PML). [18] [19] [20] PML is a ubiquitously expressed phosphoprotein that localizes to discrete nuclear structures called PML nuclear bodies (PML NBs). 21 Owing to alternative splicing, seven PML isoforms have been identified (PML I-VII). PML was originally cloned as the t(15;17) translocation partner of retinoic acid receptor alpha (RARa) found in patients with acute promyelocytic leukemia. 22 The resultant chimeric protein, PML-RARa, heterodimerizes with PML, sequesters it out of PML NBs and thereby alters the normal localization of PML from a punctate pattern to a dispersed microspeckled pattern in a dominant-negative manner. 23 PML downregulation has been shown to occur in a variety of solid tumor types as well, including the central nervous system, breast and prostate tumors, where loss of PML expression correlated with tumor progression. 20 , 24 Overexpression of PML was found to induce cell cycle arrest and inhibit the growth and tumorigenicity of a number of cancer cell lines in vitro. 25, 26 Subsequent experimentation has illustrated that p53-dependent apoptosis proceeds in a PML-dependent manner, and that pro-apoptotic factor, death-associated protein 6 requires PML for proper induction of cell death. 27, 28 These observations illustrate not only that PML has a role in tumorigenesis, but also that PML inhibits cell proliferation by inducing cell cycle arrest and by promoting apoptosis. 18 Pertinent to these studies, PML knockout mice are more susceptible not only to tumorigenesis, but also to viral infection, 29 suggesting a mechanistic connection between tumorigenesis and the replication of certain viruses.
Recent investigations of virus-host interactions have underscored the incidences of PML-mediated repression of viral replication and virus-mediated disruption of PML NBs. 30 Perhaps the best characterized example is that of HSV, in which ICP0 promotes the proteasomedependent degradation of PML early in infection to alleviate PML-mediated antiviral effects. 31, 32 Accordingly, the disruption of PML NBs by small interfering RNA-mediated knockdown of PML expression increases the plaquing efficiency of ICP0-null HSVs. 32 Given that viral and tumor cell programs deregulate PML signaling pathways to favor enhanced propagation, we hypothesized that tumor-associated deficiencies in PML expression would complement deletions of OV genes which encode proteins involved in blocking PML signaling. Here we illustrate that the oncolytic properties of IFN-sensitive viruses are defined not only by tumorassociated defects in IFN signaling, but also by aberrant PML expression. Therefore, IFN-sensitive OVs represent a new class of anti-cancer therapeutics capable of targeting cancer cells on the basis of a deficiency in PML.
Results

ICP0-null HSVs possess oncolytic properties in IFN unresponsive cancer cells
We had earlier reported that ICP0-null HSVs are cytotoxic in cancer cells that possess defects in the type I IFN pathway. 15 To further characterize the oncolytic capacities of several ICP0-null HSVs (KM100, KM110 and KM120), we screened a series of cancer cell lines for IFN responsiveness and for their susceptibility to infection by monitoring the cytopathic effects (CPE) of infection and assaying for virus yield. Parallel cultures were infected with wild-type KOS (an HSV strain) for comparison purposes. ICP0-null HSV infection of normal prostate epithelial cells (RWPE-1) and of prostate adenocarcinoma cells of the brain (DU-145) and bone (PC-3) did not yield significant CPE or elevated viral titers ( Figure 1a and data not shown). Similarly, infection of normal human osteoblasts (FOB), histiocytic lymphoma cells (U937) and chronic myelogenous leukemic cells (K562) did not elicit CPE or produce significant viral titers (Figures 1b, c and data not shown). In contrast, ICP0-null HSV infection of lymph node-derived prostate adenocarcinoma (LNCaP), osteosarcoma (U2OS) and acute promyelocyte blast (NB4) cells resulted in substantial CPE and elevated viral titers (Figures 1a-c) .
As deficiencies in the IFN response have been associated with carcinogenesis, and because ICP0-null HSVs are hypersensitive to IFN production, 33 we next determined whether sensitivity to ICP0-null HSV infection correlated with defects in the type I IFN pathway. To that end, the aforementioned cell lines in Figures 1a-c were either pretreated with IFN or mock treated with medium, and subsequently challenged with VSV-GFP (green fluorescent protein). If a cell line was responsive to IFN, then the ratio of the GFP fluorescence intensity of cultures pretreated with medium to that of cultures pretreated with IFN would be high. As shown in Figure  1d , all ICP0-null HSV-resistant cell lines in Figures 1a-c were responsive to exogenous IFN, as the GFP fluorescence intensity ratios of cultures pretreated with medium to those pretreated with IFN were high. Importantly, IFN pretreatment had no effect on GFP fluorescence intensities in the ICP0-null HSV-sensitive cell lines, LNCaP and U2OS, even at doses as high as 1000 U ml À1 ( Figure  1d ). NB4 cells were less responsive to low, more biologically relevant levels of IFN (Figure 1d ). In order to ensure these cell types could produce IFN, we either infected cells with KM120 or treated them with the double-stranded RNA mimetic polyIC and measured the production of biologically active IFN in the supernatants of cultures 16 h post-treatment through a VSV-GFP fluorescence reduction assay. In all cases, tumor cell types could produce IFN at levels that were comparable to those of their normal cell type controls (data not shown). Together, these results suggest that the oncolytic properties of ICP0-null HSVs are tumor type specific and correlate with a lack of IFN responsiveness.
Cancer cell line sensitivity to ICP0-null HSV oncolysis correlates with PML expression
To further investigate the relationship between IFN, PML and ICP0, immunofluorescence microscopy was employed to assay for the presence and subcellular localization of PML. The PG-M3 antibody was used for immunostaining, as this antibody recognizes residues 37-51, which are present in all PML isoforms. As shown in Figure 2a , RWPE-1, DU-145 and PC-3 cells possess numerous PML NBs in punctate nuclear localizations. Similar results were obtained with U937, K562 and FOB cells (Figures 2b, c) . In contrast, LNCaP and U2OS cells consistently showed fewer, less luminous PML NBs (Figures 2a, c) . NB4 cells showed diffuse nucleoplasmic and microspeckled PML, which is consistent with expression of PML-RARa (Figure 2b) . 22 Quantitative analysis of PML immunostaining relative to an internal control antibody (pan-acetyl) further illustrated a 5.16-fold lower PML expression in LNCaP cells compared with RWPE-1 cells, and a 3.45-fold lower PML expression in U2OS cells compared with FOB cells (Figures 2a-c) . These results were confirmed by western blot analysis of PML isoform expression levels in whole-cell extracts. Western blot analysis of these cell types confirmed decreased PML isoform expression levels relative to actin expression in LNCaP and U2OS cells. Taken together, these data indicate that overall levels of PML in LNCaP and U2OS cells are downregulated compared with their normal cell type controls under non-saturating immunostaining conditions. These results were independent of either fixing or permeabilizing conditions, or of the primary PML antibody used (data not shown).
As we had shown earlier that HSV ICP0 mutants induce IFN-stimulated genes in non-permissive To investigate whether PML deficiencies in cancer cells would complement ICP0-null HSV replication, we created PC-3 cells stably expressing the V5-epitopetagged fusion protein PML-RARa to disrupt PML NB architecture and PML-dependent signaling, and monitored ICP0-null HSV replication. Six PC-3PML-RARa stable clones were selected in G418 following transfection of PC-3 cells with pV5PML-RARa. Homogeneous expression of PML-RARa in each clone was determined by immunofluorescence microscopy for PML and V5 expression (Supplementary information 2 and data not shown). None of the PC-3PML-RARa clones possessed intact PML NBs. Consistent with earlier reports, five stable clones showed diffuse V5 and PML cytoplasmic and nuclear staining. 34, 35 pcDNA control-transfected PC-3 clones (PC-3pcDNA) were negative for V5 expression and possessed numerous PML NBs (Supplementary information 2).
We next characterized the sensitivities of PC-3pcDNA and PC-3PML-RARa cell lines to KM120 infection. As shown in Figure 3a , although PC-3pcDNA control cells were resistant to KM120-mediated CPE at multiplicities of infection (MOIs) as high as 10 pfu per cell, PC-3PML-RARa cells were sensitive to MOIs as low as 0.1 pfu per cell. In agreement with the CPE results, the corresponding viral growth curves from KM120-infected PC-3PML-RARa cultures were reproducibly 3 logs higher than those of KM120-infected PC-3pcDNA cultures after 3 days of infection, with significant viral titer differences occurring as early as 12 h postinfection ( Figure 3b ). KOS replication proceeded with near- In addition to the PC-3PML-RARa clone presented in Figure 3 , all PC-3PML-RARa stable clones were equally sensitive to KOS and KM120 infection, regardless of the V5 and PML staining patterns (Supplementary information 3). Also, PC-3pcDNA cells were resistant to oncolysis by KM100 and KM110, whereas PC-3PML-RARa cells were sensitive to low MOI infection (data not shown). Similar results were attained with the ICP0-null virus n212, which lacks only ICP0. Specifically in terms of viral titer assays, there was a 2.7 log difference in n212 titers comparing PC-3pcDNA cells with PC-3PML-RARa cells after a 3-day infection at an MOI of 0.5 (data not shown).
PML overexpression desensitizes cancer cell lines to ICP0-null HSV infection
To ensure that PML-RARa-associated trans-complementation of KM120 replication in PC-3 cells is a result of disrupted PML signaling, we overexpressed PML in PC-3PML-RARa cells using a replication-defective adenovirus encoding full length PML (AdPML) 25 and monitored sensitivity to ICP0-null HSV oncolysis. PML overexpression was confirmed by immunoblotting and immunofluorescence microscopy, with the latter indicating approximate transduction efficiencies of 82 and 90% in PC-3pcDNA and PC-3PML-RARa cells, respectively (Supplementary information 4 and data not shown). AdPML infection of both cell lines increased both the number and size of PML NBs for up to 4 days, while infection with the control adenovirus (AdE1E3) had no effect on PML. In agreement with earlier studies, no significant differences were observed between mockinfected and AdPML-infected PC-3pcDNA and PC-3PML-RARa cellular viabilities and growth properties up to 60 h post-AdPML infection as determined by trypan blue dye exclusion assays and alamarBlue cell proliferation assays, respectively (data not shown). 25, 26 Pre-infection of PC-3PML-RARa cells, but not of PC3pcDNA control cells, with AdPML resulted in a marked reduction in both the CPE and kinetics of KM120 infection, with an MOI of 10 being necessary to induce 50% CPE (Figure 4a and data not shown). AdE1E3 preinfection had no effect on the replication of KM120 or KOS in either cell line. AdPML expression also had no 
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PT Sobol et al effect on KOS replication in either cell type, which is consistent with earlier studies (Figure 4a , data not shown). 36 As shown in Figure 4b , at no multiplicity of KOS infection did pre-infection with AdPML affect viral titers in either PC-3pcDNA or PC-3PML-RARa cells. In contrast, AdPML pre-infection of PC-3PML-RARa cells significantly reduced KM120 viral titers at all MOIs tested, with the most significant reductions occurring at low KM120 MOIs. Similar results were attained when AdPML-pretreated PC-3PML-RARa cells were challenged with n212 infection, in that there was a 2.3 log reduction in n212 viral titers compared with AdE1E3-pretreated cultures (MOI 0.5; data not shown). As with KM120 infection, AdPML pre-treatment had no effect on n212 viral titers in PC-3pcDNA cells.
Having reversed the KM120 sensitivity phenotype of PC-3PML-RARa cells by pre-infection with AdPML, we next determined whether AdPML pre-infection could also abrogate the oncolytic activities of KM120 in other sensitive cancer cell lines. Of the three sensitive cancer cell types represented in Figure 1 , we could successfully transduce PML only in LNCaP and U2OS cells. The AdPML transduction efficiencies were 88 and 95% for LNCaP and U2OS cells, respectively (data not shown). In both cell types, AdPML infection resulted in significant increases in both the number and size of PML NBs (Figure 5a ). AdPML preinfection of LNCaP cells also significantly abrogated total KM120 viral titers at other MOIs, with the most significant attenuations occurring at low KM120 MOIs (Figure 5b) .
Similar results were obtained in U2OS cells, in that AdPML, but not AdE1E3, pre-infection resulted in significant attenuation of the CPE of KM120 infection (Figure 5c ). AdPML pre-infection of U2OS cells significantly reduced KM120 viral titers as compared with AdE1E3-infected cells, with the most significant differences occurring at MOIs less than 2.5 ( Figure 5d ). AdPML pre-infection had no effect on KOS infection at any MOI. In all cell lines tested, infection with KOS led to the complete disappearance of both endogenous and exogenous PML. As with PC-3pcDNA and PC-3PML-RARa cells, exogenous overexpression of PML did not affect either cellular viability or cellular growth rate, or metabolism as determined by trypan blue dye exclusion assays and alamarBlue cell proliferation assays (data not shown).
As exogenous overexpression of PML resulted in a substantial attenuation of the replication of ICP0-null HSVs in cancer cell types, and given that exogenous administration of IFN elicits anti-HSV effects in a PMLdependent manner, 37 we next set out to determine whether overexpression of PML in LNCaP, U2OS and PC-3PML-RARa cells alters their ability to respond to IFN. To that end, LNCaP, U2OS and PC-3PML-RARa cells were pre-infected with either AdE1E3 or AdPML, treated with varying amounts of IFN as in Figure 1d , and then challenged with VSV-GFP infection. As shown in Supplementary information 6, VSV-associated GFP fluorescence intensities were unchanged in cells treated with IFN compared with those treated with the medium, indicating that overexpression of PML in these cell types does not alter cellular IFN responsiveness. As it is feasible that PML overexpression could alter the ability of cells to produce IFN, we pre-infected the aforementioned cell types with either AdE1E3 or AdPML, treated with varying amounts of the double-stranded RNA mimetic polyIC or infected cells with KM120, and measured the amounts of biologically active IFN in the supernatants of cultures by means of a VSV-GFP plaque reduction assay on naïve Vero cells. Regardless of whether cells were pre-infected with AdE1E3 or AdPML, the amounts of biologically active IFN in the supernatants from polyIC-treated or KM120-infected cells were similar (data not shown). Together, these data indicate that exogenous expression of PML has no effect on either the production of IFN or the responsiveness to IFN in these cancer cell types.
PML predicts the oncolytic capacity of the IFN-sensitive VSV M but not the IFN-insensitive HSV G47D oncolytic virus
We next set out to determine whether PML expression affected the susceptibility of cancer cells to infection with other OVs. For these studies, we utilized the prototypic IFN-sensitive OV VSV M mutant (VSVD51-GFP) and 
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PT Sobol et al HSV-1 G47D. Cells were pre-infected with either control AdE1E3 or AdPML viruses, and subsequently challenged with either VSVD51-GFP or G47D. As shown in Figure 6a , VSVD51-GFP replicated equally well in PC-3pcDNA cells, regardless of AdPML pre-infection. However, VSVD51-GFP replication was significantly reduced in an MOI-dependent manner in AdPMLinfected PC-3PML-RARa (Figure 6b ), LNCaP ( Figure  6c ) and U2OS (Figure 6d ) cells. In contrast, G47D replication was not significantly abrogated in AdPMLpre-infected cells at any MOI. In agreement with earlier reports, 38, 39 these data suggest that VSVD51-GFP efficiently kills tumor cells that possess defects in IFN or PML signaling, whereas G47D replicates efficiently in tumor cells regardless of IFN or PML status.
Discussion
Although the clinical experiences of oncolytic virotherapy have highlighted the safety of this promising cancer-treatment modality, the lack of OV efficacy has underscored the importance of discerning which tumorassociated deficiencies promote oncolysis and which host factors abrogate tumor killing. Only by investigating these factors can optimized OVs be developed.
As part of the IFN-mediated response to viral infection, the PML tumor suppressor regulates p53-dependent apoptosis and is required for the repression of foreign gene expression. 27, 28, 35 As the viral protein ICP0 subverts the innate immune response to HSV infection by blocking the upstream IFN signaling and by promoting the proteasome-dependent degradation of PML, 12, 31 we hypothesized that cancer cells with deficiencies in PML expression or function would support ICP0-null HSV infection. Indeed, ICP0-null HSVs possess oncolytic properties in a variety of cancer cell lines that have deficiencies either in IFN responsiveness (U2OS and LNCaP cells) or in PML function (NB4 cells). Consistent with this observation, LNCaP cells lack Janus activated kinase 1, a crucial component of the IFN signaling pathway, 40 whereas U2OS cells cannot mount a sufficient antiviral response. 13 Moreover, microarray analysis of the resistant FOB and sensitive U2OS cell lines suggests that PML is upregulated approximately 10-fold in FOB cells upon oncolytic ICP0-null HSV infection, whereas no such increase in PML mRNA is observed in U2OS cells (Hummel and Mossman, unpublished data) . Taken together, these data would indicate that the global levels of several PML isoforms are downregulated in tumor cell types sensitive to ICP0-null HSV infection compared with their normal cell-type counterparts. Future investigations are aimed at understanding which PML isoforms are involved in mediating ICP0-null HSV-induced tumor cell oncolysis. In our studies, viruses harboring deletion of ICP0 alone, along with viruses harboring a second mutation were tested. In all cases, the absence of ICP0 attenuated viral replication in cells expressing PML, regardless of the presence or nature of a secondary lesion. This observation suggests that the absence of ICP0 is the predominant determinant of viral replication. Considering that viruses harboring multiple gene deletions are more attenuated in non-immortalized, non-transformed cells compared with those harboring a single deletion, we chose to develop KM100, KM110 and KM120 as oncolytic vectors given their replicative ability in tumor cells and lack of toxicity in normal cells.
Disruption of PML signaling by overexpression of the dominant-negative PML-RARa fusion protein rendered PC-3 cells sensitive to ICP0-null HSV and VSVD51 oncolysis, a phenotype that could be reversed upon PML and IFN-sensitive oncolytic viruses PT Sobol et al PML overexpression. It should be noted that although PML-RARa expression also deregulates RARa-dependent signaling pathways, such as the retinoic acid inducible gene-I antiviral pathway, PML overexpression could completely and reproducibly abrogate the oncolytic activities of these IFN-sensitive OVs in PC-3PML-RARa cells. This illustrates that the effects of PML-RARa expression in promoting viral replication were specific to deregulation of PML signaling pathways, which is supported by the experiments indicating that PML overexpression could confer resistance to KM120 oncolysis in LNCaP and U2OS cells. PML overexpression also significantly attenuated the oncolytic activities of a VSV M-mutant, which is sensitive to the effects of IFN, but not of G47D, whose oncolytic tropism is not limited to IFNunresponsive cancer cells. This observation is supported by previous research illustrating that PML-III overexpression significantly abrogated VSV replication. 41 Moreover, PML-RARa expression and PML overexpression had no effect on either the production of or the responsiveness of PC-3 cells to IFN, indicating PML abrogates OV-induced oncolysis in a manner that is independent of IFN signaling. It is to be noted that these data suggest that the NB4 cell line, which expresses PML-RARa, is only moderately responsive to IFN due to another PML-independent mechanism. Along with earlier reports on the antiviral properties of PML, these data show that PML mediates significant antiviral effects in normal cells, and that loss of PML expression or function sensitizes cancer cells to IFN-sensitive OVs. 32, 37 Earlier reports investigating the effects of PML on cell-line sensitivity to ICP0-null HSV infection illustrated that, although loss of PML expression markedly improved the plaquing efficiency of ICP0-null HSVs, PML overexpression could not confer resistance to ICP0-null HSV infection. 32, 36 Although these results seem disparate to our own findings, we agree that PML overexpression has no effect on ICP0-null HSV replication in IFN-responsive cell types. Instead, PML overexpression in IFN-unresponsive cell types, such as cancer cell lines, confers resistance to ICP0-null HSVs. Taken together with recent research illustrating that expression of the cytoplasmic PML isoform 1b confers resistance to HSV, 42 and that small interfering RNAmediated knockdown of PML expression improves the plaquing efficiency of ICP0-null HSV, 32 our results further underscore the importance of PML in mediating anti-HSV effects.
There are several mechanisms that could account for the observed inhibition of IFN-sensitive OV replication by PML. First, PML may mediate IFN-dependent inhibition of viral DNA transcription. This idea is supported by data illustrating that PML NBs are recruited to polyomavirus-like particles (VLPs) and that PML protein is required for the IFN-mediated repression of VLP transgene expression. 35 Moreover, PML NBs colocalize with several DNA virus genomes, including HSV, soon after viral adsorption. 30 Importantly, this also coincides with data illustrating that PML mediates IFNbased antiviral responses following HSV infection. 37 PML may do this by sequestering transcription factors needed for viral expression within PML NBs. Virusmediated disruption of PML NBs would then hypothetically liberate these transcription factors, driving viral genome transcription. 43 A second possible explanation relates to the similarities between PML NBs and the unfolded protein response (UPR). Nuclear inclusions containing aggregated or misfolded proteins recruit PML NBs and proteins involved in the ubiquitin-proteasome pathway, and similar aggregates can be formed following exogenous PML IV expression or by IFN treatment. 44 Although the role for PML NBs in the UPR has yet to be delineated, it is possible that PML NBs are recruited to sites of nuclear OV genome replication as an innate immune response rooted in the ubiquitin-proteasome and UPR pathways. Although these mechanisms are supported by the fact that a number of viruses disrupt PML nuclear bodies concomitantly with early viral gene expression, they do not explain the abrogation of VSV M mutant replication as VSV replicates strictly within the cytoplasm. Given that both ICP0-null and VSV M mutant viruses are hypersensitive to the effects of IFN, an additional putative mechanism is that PML mediates an anti-OV state by promoting the transcription of antiviral or antiproliferative genes and by modulating cell cycle regulation. This notion is supported by a number of studies illustrating that PML mediates the anti-proliferative properties of Rb, SMAD and p53. 18, 45, 46 Regardless of the mechanism of PML-dependent OV repression, these data illustrate that deregulation of PML expression sensitizes cancer cells to IFN-sensitive OV oncolysis. Given the many IFN-stimulated genes involved in the innate immune response to viral infection, it is intriguing that modulating the expression of only one tumor suppressive IFN-stimulated gene can have such a profound effect on OV replication. As well, it has been proposed for sometime that anti-cancer agents be designed to target defective PML signaling. We provide evidence that the IFN-sensitive OVs ICP0-null HSV and VSV M protein mutants are the first such anti-cancer agents. Although a variety of cancer types seem to lose PML expression during carcinogenesis, this effect is most notably seen in acute promyelocytic leukemia, central nervous system, prostate and colon cancers. 20 Loss of PML expression in particular cancer types and grades could potentially be used as a prognostic marker for IFNsensitive OV treatment.
Materials and methods
Cell lines and viruses
Human prostate epithelial cells (RWPE-1; American Type Culture Collection; ATCC, Manassas, VA, USA) were maintained in serum-free keratinocyte media supplemented with 25 mg ml À1 bovine pituitary extract and 0.5 ng ml À1 human epidermal growth factor (all Gibco, Carlsbad, CA, USA 25 and control parental adenovirus containing deletions in E1 and E3. 49 Briefly, AdPML encodes for PML isoform I containing exons 1, 2, 3 and a 144 bp exon 4 generated by an in-frame TGA termination codon 15 bp 3 0 to the exon 4-7 junction.
For HSV and VSV viral infections, cells seeded into 12-well dishes 24 h before infection were infected in serum-free DMEM for 1 h at the indicated MOI, followed by three washes with PBS and replacement with 5% FBS DMEM. Adenovirus infections were completed at the indicated MOI in PBS supplemented with 0.01% MgCl 2 and 0.01% CaCl 2 for 45 min.
Cytopathic effect and plaque assays
For adherent cell lines, CPE was measured 3 days postinfection following methanol fixation and Giemsa staining (Sigma). CPE in suspension cells was monitored by measuring cellular viability as determined by trypan blue dye exclusion assays (Gibco, Carlsbad, CA, USA). Viral titers from parallel cultures were measured through plaque assays. Total virus (cell and supernatant) was harvested by three rounds of freeze-thawing, followed by centrifugation at 3000 r.p.m. for 5 min. Virus was then serially diluted on U2OS cells in the presence of 3 mM hexamethylene bisacetamide (Sigma). After 2 days, cells were methanol fixed and Giemsa stained to allow for plaque quantification.
Stable PC-3PML-RARa cell lines
The pV5PML-RARa plasmid, containing C-terminal V5 and His tags, 34 was a kind gift of Suzanne Kamel-Reid (University of Toronto, Toronto, Ontario, Canada). PC-3 cells were transfected with either pV5PML-RARa or pcDNA3.1 control plasmid using GeneJuice (Novagen, San Diego, CA, USA) according to the manufacturer's protocol. Cultures were grown in 500 mg ml À1 G418
(Invitrogen, Carlsbad, CA, USA). Individual G418-resistant colonies were isolated, expanded and subsequently tested for PML-RARa expression by western blot analysis and immunofluorescence microscopy.
Immunofluorescence microscopy
Adherent cells were seeded at half-confluence on coverslips in 12-well dishes before treatment, while suspension cells were cytospun onto glass slides at 5.5 g for 5 min. Cells were fixed in 4% paraformaldehyde or formalin, permeabilized with 0.1% Triton X-100 and blocked with 2% goat serum. All antibodies were diluted in 2% goat serum. Nuclei were stained with 4',6-diamidino-2-phenylindole (Roche, Mannheim, Germany). All immunofluorescence images were taken using a Leica DM IRE2 microscope and analyzed using Openlab software (Improvision Ltd, Waltham, MA, USA). All representative images were equally contrast-enhanced for publication purposes. Details regarding quantitative analysis are outlined in Supplementary information 7.
Interferon responsiveness assays
Sub-confluent suspension or adherent cell cultures were incubated in the presence of varying amounts of human IFN-a (Sigma) for 12 h and subsequently challenged with VSV-GFP. After 24 h, GFP fluorescence was quantified in adherent cell cultures using a Typhoon Trio Variable Mode Imager (Amersham Biosciences, Piscataway, NJ, USA), whereas suspension culture supernatants were titrated on Vero cells and imaged as above. Mean GFP fluorescence intensities were normalized to those of mock-treated (non-infected) samples. The relative ratio of GFP fluorescence in cultures untreated to those pretreated with IFN was subsequently calculated.
Western blot analysis
Whole-cell extracts were prepared by washing 1 Â 10 7 cells twice in ice-cold PBS, followed by centrifugation at 200 g for 5 min at 4 1C. Cell pellets were resuspended in urea whole-cell extract buffer (9 M urea containing 10 mM Tris, pH 6.8, 10 mM b-glycerophosphate, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, 1 Â Sigma protease inhibitor cocktail) and lysed for 30 min at 4 1C.
Whole-cell lysates were clarified by centrifugation at 13 000 g for 10 min at 41C. Protein quantification of whole-cell lysates was carried out using the Bradford assay kit (Bio-Rad Laboratories; Hercules, CA, USA). Protein samples were loaded onto sodium dodecyl sulfate-polyacrylamide gels, resolved and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA) at 100 V for 1 h. All blots were blocked in 5% skim milk in Tris-buffered saline (TBS) at 4 1C overnight. Blots were incubated with TBS-Tween20 (0.1%; TBST) containing either rabbit anti-human PML (AB1370, Chemicon, Billerica, MA, USA) or goat antihuman actin (Santa Cruz Biotechnology) primary antibodies at a 1:1000 dilution for 1 h at room temperature, followed by incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies for 1 h and visualization by chemiluminescence.
